The impact of prehydration on the clearance and toxicity of high-dose methotrexate for pediatric patients

References

• Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011;118:874–883.
   PubMed Web of Science ®Google Scholar
• Whitehead VM, Shuster JJ, Vuchich MJ, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2005;19:533–536.
   PubMed Web of Science ®Google Scholar
• Csordas K, Hegyi M, Eipel OT, et al. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Anticancer Drugs 2013;24:189–197.
   PubMed Web of Science ®Google Scholar
• Buitenkamp TD, Mathot RA, de Haas V, et al. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010;95:1106–1113.
   PubMed Web of Science ®Google Scholar
• Hempel L, Misselwitz J, Fleck C, et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 2003;40:348–354.
   PubMedGoogle Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Mir O, Ropert S, Babinet A, et al. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 2010;66:1059–1063.
   PubMed Web of Science ®Google Scholar
• Cheng KK. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer. Eur J Cancer Care (Engl) 2008;17:306–311.
   PubMed Web of Science ®Google Scholar
• Schrappe M. AIEOP-BFM ALL 2009 Study. Available from: www.kinderkrebsinfo.de/health_professionals/clinical_trials/pohkinderkrebsinfotherapiestudien/aieop_bfm_all_2009/index_eng.html
   Google Scholar
• Reiter A. NHL-BFM registry 2012. Available from: www.kinderkrebsinfo.de/health_professionals/clinical_trials/closed_trials/lbl_registry/index_eng.html
   Google Scholar
• National Cancer Institute. 2006 CTCAE version 3.0. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Christensen ML, Rivera GK, Crom WR, et al. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 1988;6:797–801.
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Kurosawa Y, Kondoh K, et al. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2003;51:256–260.
   PubMed Web of Science ®Google Scholar
• Borsi JD, Revesz T, Schuler D. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1987;19:261–264.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Boyett JM, et al. Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies? Leuk Res 1997;21:435–437.
   PubMed Web of Science ®Google Scholar
• Martelli N, Mathieu O, Margueritte G, et al. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value? J Clin Pharm Ther 2011;36:237–245.
   PubMed Web of Science ®Google Scholar
• Seidel H, Nygaard R, Moe PJ, et al. On the prognostic value of systemic methotrexate clearance in childhood acute lymphocytic leukemia. Leuk Res 1997;21:429–434.
   PubMed Web of Science ®Google Scholar
• Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986;314:471–477.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:612–619.
   PubMed Web of Science ®Google Scholar
• Rask C, Albertioni F, Schroder H, et al. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996;13:359–367.
   PubMed Web of Science ®Google Scholar
• Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667–1672.
   PubMed Web of Science ®Google Scholar
• Stevens B, Croxford R, McKeever P, et al. Hospital and home chemotherapy for children with leukemia: a randomized cross-over study. Pediatr Blood Cancer 2006;47:285–292.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2013;23:53–61.
   PubMedGoogle Scholar
• Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 2013;121:5145–5153.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013; 121:898–904.
   PubMed Web of Science ®Google Scholar
• Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006;45:1227–1238.
   PubMed Web of Science ®Google Scholar
• Donelli MG, Zucchetti M, Robatto A, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995;24:154–159.
   PubMedGoogle Scholar